IL17A and rheumatoid arthritis: As there is also a clear synergy between TNF and IL17A or IL17F, bispecific antibodies that bind both TNF and IL-17 were designed with the intend to be superior for the treatment of RA, PsA and AS, and to overcome limited therapeutic responses obtained with single cytokine neutralization [401].